By

admin
IARC
Plenary themes under which authors will submit their abstracts: • Registries, research and health policy PERSONALIZE MY TREATMENT (PMT): A CANADIAN CANCER PATIENT REGISTRY. Maud Marques 1 , Karen Gambaro 1 , Vincent Normandeau-Babin 1 , David Bouffard 1 , Ethan Hoang 1 , Suzan McNamara 1 , the Exactis Network, Gerald Batist 1,2 ,...
Read More
esmo
Abstract submission deadline: Tuesday, 26 July 2022 Trial in Progress (“TiP”) abstracts Exactis-01: Clinical Utility of Returning Liquid Biopsy NGS Results in NSCL Cancer Patients – A Canadian Trial through the Exactis Network (NCT04564079) Karen Gambaro 1 , Maud Marques 1 , Andrea Hébert-Losier 1 , Suzan McNamara 1 , Gerald Batist 2 , The...
Read More
We are pleased to announce that Dr. Kostas Trakas has been appointed CEO of Exactis Innovation, effective February 1, 2022.
Read More
We are pleased to have been chosen among the 39 best clinical trial companies in Canada according to the site: https://beststartup.ca/ Here is a summary of the article: This article showcases our top picks for the best Canada based Clinical Trials companies. These startups and companies are taking a variety of approaches to innovating the...
Read More
Since their initial description in 19481, small DNA fragments travelling in the non-cellular component of internal bodily fluids and excretions have revolutionized numerous fields in public health and preventive medicine2,3,4,5,6. Although its origins have been a topic of controversy, cell-free DNA (cfDNA) is generally thought to arise from cellular breakdown mechanisms but also through active...
Read More
transcriptome alterations
Karen Gambaro, Maud Marques, Suzan McNamara, Mathilde Couetoux du Tertre, Zuanel Diaz, Cyrla Hoffert, Archana Srivastava, Steven Hébert, Benoit Samson, Bernard Lespérance, Yoo-Joung Ko, Richard Dalfen, Eve St- Hilaire, Lucas Sideris, Felix Couture, Ronald Burkes, Mohammed Harb, Errol Camlioglu, Adrian Gologan, Vincent Pelsser, André Constantin, Celia M.T. Greenwood, Sabine Tejpar, Petr Kavan, Claudia L. Kleinman,...
Read More
Exactis Innovation is a pan-Canadian research network that accelerates biomarker-led clinical and translational research in areas of high-unmet medical need. Precision Medicine in Cancer Care The past decade has seen the emergence of precision medicine, a complicated method of cancer treatment in which different molecular variants found in tumours guide oncologists to the use of...
Read More
Study of lasofoxifene versus fulvestrant in patients with metastatic breast cancer will include seven precision-medicine Exactis Network study locations COLUMBUS, Ohio (September 29, 2020) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced a collaboration with Exactis...
Read More
Exactis Innocation, cell‑free, DNA
Miguel Alcaide, Matthew Cheung, Jack Hillman, S. Rod Rassekh, Rebecca J. Deyell, Gerald Batist, Aly Karsan, AlexanderW. Wyatt, Nathalie Johnson, DavidW. Scott7 & Ryan D. Morin1* Abstract Cell-free DNA (cfDNA) has become a comprehensive biomarker in the fields of non-invasive cancer detection and monitoring, organ transplantation, prenatal genetic testing and pathogen detection. While cfDNA samples can...
Read More
1 2 3 4